Daniel J. O'Connor
Daniel J. O’Connor is the Executive Vice President of Biologics and Corporate Development for Eagle Pharmaceuticals. He joined the company in 2007 and served as finance director from 2011 to May 2013. Additionally, he served as interim chief financial officer in 2013.
Prior to joining Eagle, Mr. O’Connor held a variety of management positions, including senior analyst roles at Ethicon, a Johnson & Johnson Company subsidiary. He was also a lead finance liaison with Ethicon’s joint venture with Omrix Biopharmaceuticals. Mr. O’Connor held several finance positions at Ranbaxy Pharmaceuticals Inc., a wholly-owned subsidiary of Ranbaxy Inc. that markets generic products in the United States.
Mr. O’Connor has a B.S. in business administration from West Virginia University and an M.B.A. from Rutgers University.